查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1546300

越南學名藥市場評估：依應用、類型、品牌、給藥途徑、通路、地區、機會、預測（2017-2031）

Vietnam Generic Drugs Market Assessment, By Application, By Type, By Brand, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 121 Pages | 商品交期: 3-5個工作天內

價格

越南學名藥市場規模預計將從2023年的39億美元增至2031年的74.2億美元，2024-2031年預測期間年複合成長率為 8.39%。政府採取越來越多的措施來支持市場成長，以提高人們對學名藥及其有效性的各種好處、專利到期以及該國非傳染性疾病威脅日益增加的認識。此外，政府鼓勵外國公司投資的支持措施和藥品法的推出也支持了市場成長。2024年1月，越南衛生部宣布修訂該國藥品法，給予外國公司更多誘因和權利。該修正案擴大了投資誘因範圍，將越南的學名藥和高科技藥物製造納入其中。它還包括控制和預防社會疾病所需的藥品、生物技術產品、生物製品和疫苗。新規定也鼓勵外商投資、技術轉移以及學名藥和原料藥的研究和生產。

越南多種慢性病的流行增加了對平價藥品的需求，擴大了越南學名藥市場的規模。

根據世界衛生組織（WHO）估計，越南每年約有 115,000 人死於癌症，新診斷癌症人數為 165,000 人。為了對抗這些疾病和病症，並促進學名藥在國內的使用，政府提供了各種激勵措施來支持製藥業的發展和擴張以及高品質學名藥和創新藥物的生產。這些努力支持市場擴張。

此外，該國醫療保健行業的快速擴張、基礎設施發展投資的增加、確保基本藥物的獲取以及促進學名藥的公眾教育也支持了市場的成長。

新法規支持市場擴張

該國衛生部對藥品包裝和標籤進行了新的修訂，並於2024年 1月 15 日生效。修訂內容包括將二維碼、條碼等整合到標籤中，符合衛生部將標籤和說明書數位化、確保藥品效率、支持可追溯性等目標。該法規還要求定期更新，以確保學名藥符合品牌藥的品質和標準。這些法規目的是增強公眾對學名藥的信心，並透過提高品質和確保合規性來支持市場擴張。

非傳染性疾病增加推動市場需求

越南糖尿病、癌症、呼吸系統疾病、心血管疾病等非傳染性疾病患者數量不斷增加，帶動了越南學名藥市場的需求。根據2022年 9月發表在 PLOS ONE 上的一篇論文，非傳染性疾病是越南的主要原因之一，其中癌症、糖尿病和心血管疾病是最常見的。該國非傳染性疾病負擔的增加可歸因於城市化進程的加速和經濟成長。此外，由於地理障礙和社會經濟地位低下，生活在越南山區的人們獲得衛生服務的機會有限，因此更容易罹患非傳染性疾病。因此，非傳染性疾病的威脅日益增加，國內對學名藥的需求不斷增加。

大公司與醫院之間的合作支持市場成長

市場參與者和醫院之間加強合作以提高慢性病患者的護理品質，預計將對未來幾年的市場成長產生積極影響。2024年 6月，Vietnam National Cancer Hospital和Sandoz集團簽署了一份諒解備忘錄，以提高河內和整個越南癌症患者的照護標準。Sandoz努力改善患者獲得負擔得起的藥物的機會，包括抗感染藥物和癌症治療等領域的生物相似藥和學名藥。此外，該公司於2024年 3月與Ho Chi Minh City Oncology Hospital建立了類似的合作關係。這些夥伴關係預計將促進慢性病患者獲得學名藥。

本報告研究和分析越南學名藥市場，提供市場規模和預測、市場動態以及主要公司的狀況。

目錄

第1章 專案範圍與定義

第2章 研究方法

第3章 執行摘要

第4章 越南學名藥市場展望（2017-2031）

  • 市場規模分析與預測
    • 金額
    • 數量
  • 市佔率分析與預測
    • 依用途
    • 依類型
    • 依品牌
    • 依給藥途徑
    • 依通路
    • 依地區
    • 市佔率分析：依公司劃分（金額）（前 5 名公司及其他 -2023年）
  • 市場地圖分析（2023年）
    • 依用途
    • 依類型
    • 依品牌
    • 依給藥途徑
    • 依通路
    • 依地區

第5章 供需分析

第6章 進出口分析

第7章 價值鏈分析

第8章 波特五力分析

第9章 PESTLE分析

第10章 價格分析

第11章 市場動態

  • 市場驅動因素
  • 市場挑戰

第12章 市場趨勢與發展

第13章 監理架構與創新

  • 生物利用度/生物等效性測試
  • 監理機關的核准

第14章 專利到期

第15章 個案研究

第16章 競爭態勢

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 名的公司的SWOT 分析
  • 前10名主要企業狀況
    • DHG Pharmaceutical Joint-Stock Company
    • Sanofi-Aventis Vietnam Company Limited
    • Imexpharm Corporation
    • TRAPHACO JOINT STOCK COMPANY
    • BIDIPHAR
    • STADA Arzneimittel AG
    • Sandoz Group AG

第17章 策略建議

第18章 關於本公司，免責聲明

Product Code: MX11850

Vietnam generic drugs market is projected to witness a CAGR of 8.39% during the forecast period 2024-2031, growing from USD 3.90 billion in 2023 to USD 7.42 billion in 2031. The market's growth is supported by the government's rising measures to increase awareness about the various advantages associated with generics and their efficacy, the expiration of patents, and the growing threat of non-communicable diseases in the country. The market's growth is also supported by supportive government measures and the introduction of pharmacy laws to boost investments by foreign companies. In January 2024, the Ministry of Health in Vietnam released an amendment to the country's Pharmacy Law to give foreign companies more incentives and rights. With the amendment, the scope of investment incentives has been expanded to include generic specialty drugs, and high-tech drug manufacturing in Vietnam. It also includes drugs necessary for controlling and preventing social diseases, biotechnological products, biological products, and vaccines. The new clause also encourages foreign investments, technology transfer, and research and production of generic specialty drugs and pharmaceutical raw materials, among others.

Due to the increasing prevalence of several chronic conditions in the country, the demand for affordable medications is rising, boosting the Vietnam generic drugs market size.

According to the estimates of the World Health Organization (WHO), approximately 115,000 new deaths related to cancer and 165,000 new cases of cancer are recorded every year in Vietnam. To propel the availability of generics in the country to combat such diseases and disorders, the government has introduced various preferential policies to support the development and expansion of the pharmaceutical industry and the production of high-quality generics and innovative drugs. Such efforts are supporting the market's expansion.

Furthermore, the rapid expansion of the country's healthcare sector, increasing investments towards infrastructural development, ensuring the accessibility of required medications, and promoting education among the general population about generics are also supporting the market's growth.

New Regulations Support Market Expansion

The country's Ministry of Health introduced new amendments regarding the packaging and labeling of pharmaceutical products that went into effect on January 15, 2024. The amendments include the integration of QR codes and barcodes, among others, into the labels, aligning with the Ministry of Health's goal for electronic labeling and instructions, ensuring the efficiency of pharmaceutical products, and supporting their traceability. The regulations also require regular updates on generics to ensure that they are in alignment with the quality and standards of the original brand-name drugs. These regulations aim to improve the quality of generic drugs and ensure compliance, enhancing the population's confidence in generic drugs and supporting the market's expansion.

Rising Cases of Non-Communicable Diseases Boost Market Demand

The increasing cases of non-communicable diseases, including diabetes, cancer, respiratory diseases, and cardiovascular diseases in Vietnam, are bolstering the Vietnam generic drugs market demand. According to an article published in PLOS ONE in September 2022, non-communicable diseases are one of the leading causes of death in Vietnam, with cancer, diabetes, and cardiovascular disease being the most common. The growing burden of non-communicable diseases in the country can be attributed to increasing urbanization and economic growth. Furthermore, the individuals living in the mountainous region of the country are more vulnerable to non-communicable diseases due to limited access to healthcare services because of geographical barriers and low socioeconomic status. The increasing threat of non-communicable diseases is thus bolstering the requirement for generic drugs in the country.

Collaborations Between Key Players and Hospitals Support Market Growth

The rising collaborations between the key players of the market and hospitals to improve the quality of care for patients battling chronic conditions are expected to influence the market's growth in the coming years positively. In June 2024, Vietnam National Cancer Hospital and Sandoz Group AG signed a Memorandum of Understanding (MoU) to improve the standard of care for patients suffering from cancer in Hanoi and around the country. Sandoz is committed to improving patient access to affordable medications, including biosimilars and generics, in the field of anti-infectives and oncology, among others. Additionally, the company entered a similar partnership with Ho Chi Minh City Oncology Hospital in March 2024. Such collaborations are expected to boost the availability of generics for patients with chronic conditions.

Biosimilars Hold Significant Market Share

The growth of the segment can be attributed to the increasing preference for lower-cost alternatives due to the rising costs of prescription drugs in Vietnam. The increasing introduction of biosimilars also supports the growth of the Vietnam generic drugs market. In March 2022, Shanghai Henlius Biotech, Inc. collaborated with Getz Pharma Limited to commercialize Handayuan, an adalimumab biosimilar, across several countries in Africa and Asia. The supply and licensing agreement will allow the latter to market the biosimilar in Vietnam, Ukraine, Sri Lanka, Myanmar, Cambodia, Philippines, and Uzbekistan, among others. Such agreements and collaborations are expected to boost the accessibility of biosimilars in Vietnam, supporting the segment's expansion and growth of the Vietnam generic drugs market.

Future Market Scenario (2024-2031F)

As per the Vietnam generic drugs market analysis, the market is expected to witness significant growth in the coming years owing to rising investments in pharmaceutical manufacturing, the growing prevalence of chronic diseases, and increasing government initiatives to bolster the utilization of generics. Additionally, as the market expansion continues, it is expected to provide lucrative growth opportunities for both international and domestic pharmaceutical companies. The increasing measures by the government to ensure the availability of affordable medications are also expected to propel the demand for generic drugs in Vietnam.

Key Players Landscape and Outlook

The increasing investments by the leading market players in modern medicines are supporting the market's expansion. In April 2024, TRAPHACO JOINT STOCK COMPANY announced that they would focus on enhancing their research and development capabilities as well as new technology products and launch their first generic drugs. To facilitate these goals, the company is recruiting external research and development experts and increasing its investments toward enhancing its workforce and internal departments. Such investments are expected to boost the manufacture of generic drugs in Vietnam and provide lucrative growth opportunities to the market.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Vietnam Generic Drugs Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Application
      • 4.2.1.1. Neurovascular
      • 4.2.1.2. Cardiovascular
      • 4.2.1.3. Dermatology
      • 4.2.1.4. Oncology
      • 4.2.1.5. Diabetology
      • 4.2.1.6. Respiratory
      • 4.2.1.7. Others
    • 4.2.2. By Type
      • 4.2.2.1. Biosimilar Generics
      • 4.2.2.2. Small Molecule Generics
    • 4.2.3. By Brand
      • 4.2.3.1. Branded Generic
      • 4.2.3.2. Pure Generic
    • 4.2.4. By Route of Administration
      • 4.2.4.1. Oral
      • 4.2.4.2. Injectable
      • 4.2.4.3. Topical
      • 4.2.4.4. Others
    • 4.2.5. By Distribution Channel
      • 4.2.5.1. Hospital Pharmacy
      • 4.2.5.2. Retail Pharmacy
      • 4.2.5.3. Online Pharmacy
    • 4.2.6. By Region
      • 4.2.6.1. North
      • 4.2.6.2. South
      • 4.2.6.3. Central
    • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Application
    • 4.3.2. By Type
    • 4.3.3. By Brand
    • 4.3.4. By Route of Administration
    • 4.3.5. By Distribution Channel
    • 4.3.6. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

  • 11.1. Market Drivers
  • 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

  • 13.1. Bioavailability/Bioequivalence Studies
  • 13.2. Regulatory Approvals

14. Patent Expiration

15. Case Studies

16. Competitive Landscape

  • 16.1. Competition Matrix of Top 5 Market Leaders
  • 16.2. SWOT Analysis for Top 5 Players
  • 16.3. Key Players Landscape for Top 10 Market Players
    • 16.3.1. DHG Pharmaceutical Joint-Stock Company
      • 16.3.1.1. Company Details
      • 16.3.1.2. Key Management Personnel
      • 16.3.1.3. Products and Services
      • 16.3.1.4. Financials (As Reported)
      • 16.3.1.5. Key Market Focus and Geographical Presence
      • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 16.3.2. Sanofi-Aventis Vietnam Company Limited
    • 16.3.3. Imexpharm Corporation
    • 16.3.4. TRAPHACO JOINT STOCK COMPANY
    • 16.3.5. BIDIPHAR
    • 16.3.6. STADA Arzneimittel AG
    • 16.3.7. Sandoz Group AG

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Vietnam Generic Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Vietnam Generic Drugs Market, By Volume, In Number of Prescriptions, 2017-2031F
  • Figure 3. Vietnam Generic Drugs Market Share (%), By Application, 2017-2031F
  • Figure 4. Vietnam Generic Drugs Market Share (%), By Type, 2017-2031F
  • Figure 5. Vietnam Generic Drugs Market Share (%), By Brand, 2017-2031F
  • Figure 6. Vietnam Generic Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 7. Vietnam Generic Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 8. Vietnam Generic Drugs Market Share (%), By Region, 2017-2031F
  • Figure 9. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 10. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 11. By Brand Size Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 12. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 13. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 14. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023